1. Introduction {#s0005}
===============

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. More than 15% of patients with OS develop metastases, frequently to lung [@bib1]. For patients with metastasis or recurrence, the long-term survival rate is less than 20% [@bib2], [@bib3]. Understanding of the molecular mechanisms of OS would provide a basis for developing new therapeutic strategies.

It has been demonstrated that genetic alternations in the status of DNA methylation count among the most common molecular alterations in human neoplasia [@bib4]. DNA methylation usually results in obstruction of the promoter region, hampering gene transcription and causing gene silencing [@bib5]. Quite a few studies have reported findings related to DNA methylation in OS. It has been reported that methylation of frizzled-related proteins (SFRPs) may promote Wnt signaling pathway, thereby enhancing OS cell invasion [@bib6]. Hyper-methylation of p14ADP-ribosylation factor (ARF) and estrogen receptor 1 (ESR1) have been found in OS as well, and may have implications in the prognosis of OS patients [@bib7]. Moreover, Lu et al. [@bib8] have reported that iroquois homeobox 1 (IRX1) enhances OS metastasis and may be a potential molecular marker. Recent study [@bib9] suggests that promoter hyper-methylation of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) is a causative factor in metastasis of OS. Despite some advances have been achieved in this field, certain mechanisms underlying OS remain largely unknown. Microarray analysis has been applied to identify the gene alterations and screen potential targets in human OS cell lines [@bib10]. Kresse et al. [@bib11] integrated genomewide genetic and epigenetic profiles from the EuroBoNeT panel, a European Network of Excellence on bone tumors (<http://www.eurobonet.eu>), of 19 human osteosarcoma cell lines based on microarray technologies, and deposited the DNA methylation dataset in the Gene Expression Omnibus (GEO) data repository (accession number GSE36002). In their study, they have comprehensively analyzed the relationships of DNA copy number, DNA methylation and mRNA expression in OS. Additionally, they screened out the differentially methylated genes and performed functional enrichment analysis. However, the interaction between differentially methylated genes, and the classification of these genes have not been analyzed.

Since methylation of CpG islands in promoter regions is a mechanism for inactivating genes, we estimated the differentially methylated genes in promoter regions between OS and normal samples from GSE36002 in this study. Pathway and functional enrichment analyses of differentially methylated genes was then performed. Subsequently, protein-protein interaction (PPI) network was constructed to analyze the interactions between differentially methylated genes. Furthermore, the classifications of differentially methylated genes, including tumor suppressor (TS) genes, oncogenes and TFs were investigated.

2. Materials and methods {#s0010}
========================

2.1. DNA methylation microarray data {#s0015}
------------------------------------

The GSE36002 DNA methylation microarray data [@bib11] were downloaded from GEO database in National Center of Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/gds/>), based on the platform of Illumina Human Methylation 27 BeadChip (Illumina Inc., California, USA). GSE36002 dataset is comprised of 25 samples: 19 osteosarcoma cell lines samples and 6 normal control samples (four normal bone samples and two osteoblast cultures).

2.2. Identification of differentially methylated genes {#s0020}
------------------------------------------------------

DNA methylation microarray data were processed with simple scaling normalization using Lumi package (<http://bioconductor.org/packages/release/bioc/html/lumi.html>) [@bib12], [@bib13] in Bioconductor [@bib14]. Subsequently, the differentially methylated regions (DMR) between osteosarcoma and normal samples were identified using methyAnalysis with M-value\>1 and false discovery rate (FDR)\<0.01.

M-values were calculated by the formula:$${M - {value} = \log 2}\frac{methylated\ probe\ intensity}{unmethylated\ probe\ intensity}$$

FDR method is also called Benjamini and Hochberg (BH) method [@bib15], used to adjust p value. In detail, the original p values of all genes were ranked in descending order. The maximum p value was assigned as n, and the minimum was assigned as 1. The adjusted p value (FDR) was calculated as followed:$${FDR} = {original} p{value}*\left( {n/i} \right)$$where n represents the number of all genes; i represents the ith p value (from minimum to maximum).

The identified DMR were performed gene annotation to screen the differentially methylated sites located in promoter region. Dkhil et al. [@bib16] have reported that most of the promoters display the changes of DNA methylation in their Ups-regions, which are between +500 and +2000 bp upstream from the transcription start site of genes. Therefore, in consideration of numerous genes in the dataset, the promoter region was defined as 2000 bp upstream of the transcription start site in this study.

2.3. Functional enrichment analysis of differentially methylated genes {#s0025}
----------------------------------------------------------------------

Functional enrichment analyses included Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Reactome pathways and Gene Ontology (GO) terms analyses. The differentially methylated genes were performed functional enrichment analysis using GOFunction (<http://www.bioconductor.org/packages/release/bioc/html/GOFunction.html>) in R package. P value\<0.05 and count (number of significantly enriched genes)≥2 were used as thresholds.

2.4. PPI network construction {#s0030}
-----------------------------

PPI analysis can provide new insights into protein function, and uncover the generic organization principles of functional cellular networks [@bib17]. Therefore, we constructed PPI network to further analyze the functions of differentially methylated gene. The Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://www.mybiosoftware.com/pathway-analysis/7789>) provides the information of both experimental and predicted interactions [@bib18]. With this tool, the differentially methylated gene pairs with significant interactions (combine score\>0.9) were identified and used for construction of PPI network which was visualized using Cytoscape (<http://cytoscape.org/>) [@bib19]. In the network, the nodes with higher degrees were defined as hub nodes.

2.5. Gene classification analysis {#s0035}
---------------------------------

Based on tumor suppressor (TS) genes database [@bib20] and tumor associated genes (TAG) database [@bib21], the known TS genes and oncogenes were selected from the obtained differentially methylated genes.

2.6. TF analysis {#s0040}
----------------

On the basis of the TF-target gene pairs in Encode [@bib22], [@bib23], the differentially methylated genes corresponding to the differentially methylated TFs were identified. Then according to the obtained TF-target gene interaction pairs, significant TFs (p value\<0.01) were screened using hypergeometric analysis. The formula of hypergeometric distribution was shown as follows:$$P\left( {X = k} \right) = \frac{C_{M}^{k}C_{N - M}^{n - k}}{C_{N}^{n}}{k \in}\left\{ {0,1,2,\ldots m} \right\}$$where N represents the total number of genes; n represents the number of target genes regulated by TF; M represents the number of differentially methylated genes; k represents the number of differentially methylated genes regulated by TF.

3. Results {#s0045}
==========

3.1. Identification of differentially methylated genes {#s0050}
------------------------------------------------------

In the study, a total of 2845 differentially methylated loci were identified in OS samples relative to normal samples, including 1379 hyper-methylation regions and 169 hypo-methylation regions in the promoter region. Additionally, the numbers of hyper- and hypo-methylated loci in enhancers are shown in [Table 1](#t0005){ref-type="table"}, and in exons and other regions are shown in [Table 2](#t0010){ref-type="table"}.Table 1The numbers of hyper- and hypo-methylated loci in enhancer region.Table 1**EnhancerHyperHypoTotal**TRUE43163206FALSE149010712561Table 2The numbers of hyper- and hypo-methylated loci in exon, promoter and other regions.Table 2**RegionsHyperHypoTotal**1stExon574895463\'UTR3811Body84619703IGR122537Promoter13791691548[^1]

3.2. Functional enrichment analyses of differentially methylated genes {#s0055}
----------------------------------------------------------------------

Pathway enrichment analysis revealed that the differentially hyper-methylated genes were significantly enriched in KEGG pathways including Pathways in cancer, Bladder cancer, Neuroactive ligand-receptor interaction, and Peroxisome proliferator-activated receptor (PPAR) signaling pathways ([Table 3](#t0015){ref-type="table"}). The differentially hypo-methylated genes were significantly related to Cytokine-cytokine receptor interaction and Toll-like receptor signaling pathways ([Table 4](#t0020){ref-type="table"}). With regard to Reactome pathways, the differentially hyper-methylated genes were primarily enriched in Gastrin-CREB signaling pathway via PKC and MAPK, and G alpha (q) signaling events pathway, while the differentially hypo-methylated genes were mainly enriched in Defensins, and Alpha-defensins pathways ([Table 5](#t0025){ref-type="table"}). For GO function, the differentially hyper-methylated genes were predominately enriched in developmental process and anatomical structure development ([Table 6](#t0030){ref-type="table"}), while the differentially hypo-methylated genes were primarily enriched in extracellular region ([Table 7](#t0035){ref-type="table"}).Table 3Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (top 10) of the differentially hyper-methylated genes.Table 3**KEGG IDNameGene countP value5200**Pathways in cancer400.002712**4080**Neuroactive ligand-receptor interaction340.004135**3320**PPAR signaling pathway120.007642**4974**Protein digestion and absorption130.009805**4512**ECM-receptor interaction130.014496**5219**Bladder cancer80.014911**4920**Adipocytokine signaling pathway110.015917**5414**Dilated cardiomyopathy130.022575**4916**Melanogenesis140.025452**4340**Hedgehog signaling pathway90.028947[^2]Table 4The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (top 10) of the differentially hypo-methylated genes.Table 4**KEGG IDNameGene countP value4740**Olfactory transduction100.004797**5320**Autoimmune thyroid disease30.015042**4060**Cytokine-cytokine receptor interaction70.016163**4620**Toll-like receptor signaling pathway40.018845**4950**Maturity onset diabetes of the young20.025692**830**Retinol metabolism30.026061**4622**RIG-I-like receptor signaling pathway30.034039**982**Drug metabolism - cytochrome P45030.036526**4140**Regulation of autophagy20.045367[^3]Table 5The reactome pathways (top 5) of the differentially hyper- and hypo-methylated genes.Table 5**Reactome IDNameGene countP valueDifferentially hyper-methylated genes881907**Gastrin-CREB signaling pathway via PKC and MAPK346.26E−06**416476**G alpha (q) signaling events298.10E−05**163685**Integration of energy metabolism190.000224877**500792**GPCR ligand binding510.000330922**1474244**Extracellular matrix organization350.000489987**Differentially hypo-methylated genes1461973**Defensins74.84E−07**1462054**Alpha-defensins30.000113**1592389**Activation of Matrix Metalloproteinases40.000245**381753**Olfactory Signaling Pathway110.000577**1461957**Beta defensins40.000602[^4]Table 6The gene ontology (GO) of the differentially hyper-methylated genes.Table 6**GO categoriesNameGene countP valueBP**Developmental process4831.11E−16Anatomical structure development4362.22E−16System development3874.44E−16Cell differentiation3232.00E−15**CC**Extracellular region part1411.79E−10Plasma membrane part2111.14E−09Proteinaceous extracellular matrix601.29E−09Extracellular matrix641.22E−08**MF**Sequence-specific DNA binding923.03E−08Sequence-specific DNA binding RNA Polymerase II transcription factor activity468.37E−07Voltage-gated cation channel activity289.45E−07Sequence-specific DNA binding transcription factor activity1181.16E−06[^5]Table 7The gene ontology (GO) of the differentially hypomethylated genes.Table 7**GO categoriesNameGene countP valueBP**Keratinocyte differentiation93.54E−07Epidermal cell differentiation107.98E−07Keratinization61.88E−06Defense response293.62E−06**CC**Extracellular region503.73E−11Extracellular space231.18E−06Extracellular region part271.81E−06Extracellular region503.73E−11**MF**Serine-type endopeptidase activity82.01E−05Serine-type peptidase activity85.12E−05Serine hydrolase activity85.56E−05Monooxygenase activity68.15E−05[^6]

3.3. PPI network construction {#s0060}
-----------------------------

In this study, a PPI network with 442 nodes and 693 PPI pairs was constructed ([Fig. 1](#f0005){ref-type="fig"}). In this network, adenylate cyclase 2 (*ADCY2*) (degree=34), proopiomelanocortin (*POMC*) (degree=29), signal transducers and activators of transcription *(STAT3*) (degree=21), neuropeptide Y (*NPY*) (degree=20), and somatostatin (*SST*) (degree=18) with degrees more than 17 were regarded as hub nodes. The sub-network modules that contained the five hub nodes are shown in [Fig. 2](#f0010){ref-type="fig"}A--E.Fig. 1A protein-protein interaction network of differentially methylated genes. Red nodes stand for differentially hyper-methylated genes, while green nodes stand for differentially hypo-methylated genes.Fig. 1Fig. 2The networks that contained five hub genes of adenylate cyclase 2 (*ADCY2*), proopiomelanocortin (*POMC*), signal transducers and activators of transcription *(STAT3*), neuropeptide Y (*NPY*), and somatostatin (*SST*). Red nodes stand for differentially hyper-methylated genes, while green nodes stand for differentially hypo-methylated genes.Fig. 2

3.4. Gene classification analysis {#s0065}
---------------------------------

Among the identified differentially hyper-methylated genes, 27 were found to be oncogenes, 78 were TS genes and 22 were tumor-associated genes (oncogenes or TS genes). The identified differentially hypo-methylated genes contained one oncogene, five TS genes and one tumor-associated gene.

3.5. TF analysis {#s0070}
----------------

A total of 76 TFs that were significantly enriched in target genes were identified ([Supplementary material Fig. 1](#s0095){ref-type="sec"}). Among these TFs, MAX interactor 1, dimerization protein (MXI1), STAT3, and T-cell acute lymphocytic leukemia 1 (TAL1) were also cancer-associated TFs. Interestingly, STAT3 was a hub node in the PPI network. Furthermore, the methylation levels of the three TFs were up-regulated in OS samples relative to control samples ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3The methylation levels of *MXI1*, *STAT3* and *TAL1* in all samples. Horizontal axis represents 25 samples, and vertical axis represents the M value of methylation level of *MXI1*, *STAT3* and *TAL1*.Fig. 3

4. Discussion {#s0075}
=============

OS is a rare malignant tumor with a high tendency of metastasis. Aberrant methylation of tumor-related genes in the promoter region is associated with human tumors [@bib24]. In the current study, a total of 2845 differentially methylated loci were identified in OS samples compared to normal samples, including 1379 hyper-methylation regions and 169 hypo-methylation regions in the promoter region. Although so many differentially methylated loci were identified, not all of them may involve in OS progression. Further analyses revealed that the differentially hypo-methylated genes were significantly enriched in Toll-like receptor signaling pathway, while differentially hyper-methylated genes were significantly enriched in Neuroactive ligand-receptor interaction pathway, and PPAR signaling pathway. Additionally, *ADCY2* and *POMC* had the top two highest degrees in the PPI network. Moreover, MXI1, STAT3, and TAL1 were significant TFs enriched with target genes, and they were also tumor-associated TFs.

Toll-like receptors play important roles in the innate immune system, especially in inflammatory response, which is considered to be an important epigenetic factor contributing to neoplasia and tumor progression [@bib25], [@bib26]. Triggering of toll-like receptor 4 (TLR4) on metastatic breast cancer cells has been found to promote adhesion and invasive migration of tumor cells [@bib27]. There is evidence that inflammatory cytokines, such as TNF-α and IL-1 are required for promoting the tumorigenesis of osteosarcoma [@bib28]. The present study found that the differentially hypo-methylated genes in OS samples were related to Toll-like receptor signaling pathway. These findings led to a speculation that the differentially hypo-methylated genes and the Toll-like receptor signaling pathway might be involved in OS-related inflammation. A recent microarray analysis reported that Neuroactive ligand-receptor interaction pathway and PPAR signaling pathway were associated with OS metastasis [@bib29]. Moreover, it has been established that PPAR agonists can suppress OS proliferation and growth, and induce apoptosis [@bib30]. Results of this study suggest that the roles of Neuroactive ligand-receptor interaction pathway and PPAR signaling pathway in OS may be partly due to hyper-methylation of genes.

It has been reported that PPI network can organize all protein-coding genes into a large network which provides a better understanding of the functional organization of the proteome [@bib17]. In the present study, PPI analysis found that *ADCY2* and *POMC* had the top two highest degrees in the constructed PPI network. Genome-wide studies have shown that deletion of a hub protein is more likely to be lethal than deletion of a non-hub protein. As a result, hub nodes may play more important roles in OS than the other nodes. Presently, we focused on the top two nodes with higher degrees for discussion. Interestingly, they have been reported to be implicated in the progression of OS. Recently, Sun et al. [@bib31] performed gene expression profiling analysis of OS cell lines, and found that *ADCY2* was involved in purine metabolism pathway in OS. POMC has been found in osteoclasts [@bib32], which is a precursor of β-endorphin. Baamonde et al. [@bib33] reported that endogenous β-endorphin involved in the initial stages of murine OS. Taken together, our study may further suggested the role of *ADCY2* and *POMC* in OS.

*STAT3* is a member of STAT protein family and plays a critical role in cell growth and apoptosis [@bib34]. Increasing studies have established that STAT3 activation promotes the development of OS [@bib35], [@bib36]. *STAT3* was found to be hyper-methylated in OS samples in the present study, suggesting that *STAT3* might play a role in OS. It has been reported that STAT3 had an oncogenic or a tumor suppressor role in human brain tumor depending on the mutational profile of the tumor [@bib37]. It indicates that *STAT3* may also play dual roles in promoting or discouraging the development of OS. Moreover, *STAT3* was a hub node (degree=21) in the PPI network of this study, suggesting that the role of *STAT3* in OS might be associated with its interactions with other proteins.

*MXI1* is a member of the *MAD* gene family, which plays a key role in regulating cell proliferation and growth [@bib38], [@bib39]. It is located at 10q24-25, where loss of heterozygosity occurs in several human cancers, including endometrial cancers, prostate tumors, gliomas, renal cell carcinomas, and small-cell lung cancers [@bib40]. Importantly, numerous experiments have verified that *MXI1* functions as a tumor suppressor gene via negatively modulating the promoter of oncogene c-Myc, which is involved in the control of cell proliferation and apoptosis [@bib41], [@bib42], [@bib43], [@bib44]. To our knowledge, the role of *MXI1* in OS remains unclear. The study revealed hyper-methylation of *MXI1* in OS. In light of these results, we speculate that *MXI1* may inhibit progression of OS by compromising cell proliferation and inducing apoptosis. TAL1 is a basic helix-loop-helix TF required for blood cell development [@bib45]. In the study of Kresse et al. [@bib46], *TAL1* was found to be significantly differentially methylated between OS and normal control samples. In agreement with the study above, the present study also revealed that it was a differentially methylated gene and a tumor-associated TF. Therefore, TAL1 might be an important TF associated with OS.

In this study, some limitations have to be acknowledged. First, the sample size was a little small. Second, no experiment was conducted to validate the expression level of these methylated genes, including *MXI1*, *STAT3* and *TAL1*. Therefore, further studies with more samples and experimental validations are needed to validate our results.

Taken together, microarray analysis of epigenetic alterations revealed that Neuroactive ligand-receptor interaction pathway, PPAR signaling pathway and toll-like receptor signaling pathway may be implicated in tumorigenesis of OS. MXI1, STAT3, and TAL1 might be critical TFs in development of OS. Results of the study provide more enlightening insights concerning the association of DNA methylation with tumorigenesis of OS. More studies are warranted to verify these results.
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[^1]: UTR: untranslated regions; IGR: intergenic region.

[^2]: Gene count represents the number of gene enriched in the pathway.

[^3]: Gene count represents the number of gene enriched in the pathway.

[^4]: Gene count represents the number of gene enriched in the pathway.

[^5]: BP: biological process; CC: cellular component; MF: molecular function; Gene count represents the number of gene enriched in GO term.

[^6]: BP: biological process; CC: cellular component; MF: molecular function; Gene count represents the number of gene enriched in GO term.
